- Home
- VGI vs CMRX Comparison
VGI vs CMRX Comparison
Compare VGI & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- CMRX
- Stock Information
- Founded
- VGI 2012
- CMRX 2000
- Country
- VGI United States
- CMRX United States
- Employees
- VGI N/A
- CMRX N/A
- Industry
- VGI Investment Managers
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- VGI Finance
- CMRX Health Care
- Exchange
- VGI Nasdaq
- CMRX Nasdaq
- Market Cap
- VGI 91.4M
- CMRX 77.1M
- IPO Year
- VGI N/A
- CMRX 2013
- Fundamental
- Price
- VGI $7.80
- CMRX $2.79
- Analyst Decision
- VGI
- CMRX Strong Buy
- Analyst Count
- VGI 0
- CMRX 2
- Target Price
- VGI N/A
- CMRX $8.50
- AVG Volume (30 Days)
- VGI 46.0K
- CMRX 11.2M
- Earning Date
- VGI 01-01-0001
- CMRX 11-07-2024
- Dividend Yield
- VGI 12.66%
- CMRX N/A
- EPS Growth
- VGI N/A
- CMRX N/A
- EPS
- VGI N/A
- CMRX N/A
- Revenue
- VGI N/A
- CMRX $159,000.00
- Revenue This Year
- VGI N/A
- CMRX N/A
- Revenue Next Year
- VGI N/A
- CMRX $1,690.28
- P/E Ratio
- VGI N/A
- CMRX N/A
- Revenue Growth
- VGI N/A
- CMRX N/A
- 52 Week Low
- VGI $6.68
- CMRX $0.75
- 52 Week High
- VGI $7.99
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- VGI 30.56
- CMRX 84.35
- Support Level
- VGI $8.00
- CMRX $2.74
- Resistance Level
- VGI $8.18
- CMRX $3.02
- Average True Range (ATR)
- VGI 0.08
- CMRX 0.26
- MACD
- VGI -0.03
- CMRX 0.18
- Stochastic Oscillator
- VGI 0.00
- CMRX 77.13
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.